戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 w oxygen affinity state (i.e. treatment with inositol hexaphosphate).
2 ate upon addition of an allosteric effector, inositol hexaphosphate.
3 such as protons, 2,3-biphosphoglycerate, and inositol hexaphosphate.
4                   Inositol-trisphosphate and inositol-hexaphosphate also partially supported activati
5                              The addition of inositol hexaphosphate, an allosteric effector, causes r
6  hindered by the presence of phytic acid, or inositol hexaphosphate, an anti-nutritional factor that
7                           In the presence of inositol hexaphosphate and bezafibrate (or derivatives),
8 ons, semihemoglobins responded to effectors (inositol hexaphosphate and L35) by decreasing the affini
9 on state upon adding an allosteric effector, inositol hexaphosphate, and reducing the temperature.
10 upon the addition of an allosteric effector, inositol hexaphosphate, and/or by reducing the temperatu
11  exhibits a stronger response to 2,3-BPG and inositol hexaphosphate as compared to Hb F.
12 T binds to a single site and is displaced by inositol hexaphosphate at a 1:1 mol ratio, indicating th
13                                        Since inositol hexaphosphate binding to syndecan-4 does not pr
14 ophosphate diesters by P NMR and accumulated inositol hexaphosphate by XANES were observed in surface
15 tions of low pH (pH 6.35) in the presence of inositol-hexaphosphate, COHb assumes an altered R-state.
16 nto a sample of deoxy-HbA with the effector, inositol hexaphosphate, encapsulated in a porous sol-gel
17 indicate a differential allosteric effect by inositol hexaphosphate for HbC approximately HbS > HbA.
18      Blocking the 2, 3-DPG binding site with inositol hexaphosphate (IHP) resulted in a selective red
19 ctors, 2,3-bisphosphoglycerate (2,3-BPG) and inositol hexaphosphate (IHP), is decreased relative to t
20                     The allosteric effector, inositol hexaphosphate (IHP), promotes fiber formation,
21 ence and presence of an allosteric effector, inositol hexaphosphate (IHP), using 15N-1H residual dipo
22 ence and presence of an allosteric effector, inositol hexaphosphate (IHP), using a stretched polyacry
23 ave been measured at pH 7 in the presence of inositol hexaphosphate (IHP).
24 pH 6 and pH 8 in the presence and absence of inositol hexaphosphate (IHP).
25 nd in the absence of an allosteric effector, inositol hexaphosphate (IHP).
26 nding of a heterotropic allosteric effector, inositol hexaphosphate (IHP).
27                           In the presence of inositol hexaphosphate, IHP, none of them exhibits coope
28 resence and absence of the organic phosphate inositol hexaphosphate, IHP.
29 ow-concentration Hb solution when induced by inositol-hexaphosphate in the presence of polyethylene g
30                                Hydrolysis of inositol hexaphosphate (InsP6 , the substrate for phytas
31                                              Inositol hexaphosphate (InsP6) is the most abundant inos
32 ogen Ralstonia solanacearum, in complex with inositol hexaphosphate (InsP6), acetyl-coenzyme A (AcCoA
33 hat the Dbp5 ATPase is activated by Gle1 and inositol hexaphosphate (IP(6)).
34            Here, we assessed the efficacy of inositol hexaphosphate (IP6) against invasive human pros
35                                              Inositol hexaphosphate (IP6) causes G(1) arrest and incr
36          The total phenolic compounds (TPC), inositol hexaphosphate (IP6), reduced (GSH) and oxidised
37 ast Ino80 complexes and is also inhibited by inositol hexaphosphate (IP6).
38 possess enhanced cooperativity in vitro when inositol hexaphosphate is present.
39 strengthened when the effector molecule IHP (inositol hexaphosphate) is added to deoxy-desArgalpha141
40 4/beta15) of both chains, 3) displacement by inositol hexaphosphate of the Hb-bound 8-hydroxy-1,3,6-p
41  decreased capacity for the synthesis of myo-inositol hexaphosphate (phytic acid) and a concomitant i
42                      SNF472, intravenous myo-inositol hexaphosphate, selectively inhibits the formati
43 nd to a novel peptide-based inhibitor and to inositol hexaphosphate suggests a molecular basis of sub
44         Addition of the allosteric modulator inositol hexaphosphate to increase Hb P50 and the thiol
45 al change by adding the allosteric effector, inositol hexaphosphate, to the fluoromet-Hb sample.